



Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC

Toshiaki Iwase, Kenichi Harano, Hiroko Masuda, Kumiko Kida, Kenneth R Hess, Ying Wang, Luc Dirix, Steven J van Laere, Anthony Lucci, Savitri Krishnamurthy, et al.

► To cite this version:

Toshiaki Iwase, Kenichi Harano, Hiroko Masuda, Kumiko Kida, Kenneth R Hess, et al.. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, 2020, 20 (1), pp.430. 10.1186/s12885-020-06940-z . inserm-02913696

HAL Id: inserm-02913696

<https://inserm.hal.science/inserm-02913696>

Submitted on 10 Aug 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH ARTICLE

Open Access



Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC

Toshiaki Iwase^{1,2}, Kenichi Harano^{1,2}, Hiroko Masuda^{1,2}, Kumiko Kida^{1,2}, Kenneth R. Hess³, Ying Wang⁴, Luc Dirix⁵, Steven J. Van Laere⁵, Anthony Lucci^{1,6}, Savitri Krishnamurthy^{1,7}, Wendy A. Woodward^{1,8}, Rachel M. Layman^{1,9}, François Bertucci¹⁰ and Naoto T. Ueno^{1,2*} 

Abstract

Background: The purpose of this study was to determine the prognostic role of hormone receptor (HR) on inflammatory breast cancer (IBC) to elucidate its aggressive biological behavior.

Methods: We evaluated the expression of estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemical staining and determined the predictive and prognostic role of HR expression on 189 patients with HR+/HER2- IBC and 677 patients with HR+/HER2- stage III non-IBC. Furthermore, we performed gene expression (GE) analyses on 137 patients with HR+/HER2- IBC and 252 patients with HR+/HER2- non-IBC to detect genes that are specifically overexpressed in IBC.

Results: The expression of ER% was significantly associated with longer distant disease-free survival and overall survival. However, there was no significant relationship between ER% and neoadjuvant chemotherapy outcome. In the GE study, 84 genes were identified as significantly distinguishing HR+ IBC from non-IBC. Among the top 15 canonical pathways expressed in IBC, the ERK/MAPK, PDGF, insulin receptor, and IL-7 signaling pathways were associated with the ER signaling pathway. Upregulation of the *MYC* gene was observed in three of these four pathways. Furthermore, HR+/HER2- IBC had significantly higher *MYC* amplification, and the genetic alteration was associated with poor survival outcome.

Conclusions: Higher ER expression was significantly associated with improved survival in both HR+/HER2- IBC and HR+/HER2- stage III non-IBC patients. HR+/HER2- IBC had several activated pathways with *MYC* upregulation, and the genetic alteration was associated with poor survival outcome. The results indicate that *MYC* may be a key gene for understanding the biology of HR+/HER2- IBC.

Keywords: Inflammatory breast neoplasms, Estrogen receptors, Immunohistochemistry, Gene expression

* Correspondence: nueno@mdanderson.org

¹Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

²Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Inflammatory breast cancer (IBC) is a rare type of breast malignancy characterized by diffuse erythema and edema called *peau d'orange* without palpable mass. The incidence is approximately 2.0 to 2.5% in a U.S. national survey [1]. This phenotype is also known to have a very aggressive tumor behavior, with a 2.9- to 4.2-year median survival period, which is a significantly poorer survival period than that in locally advanced non-IBC [1, 2].

Estrogen receptor (ER) and progesterone receptor (PR) expression by immunohistochemical (IHC) analysis is commonly used as a predictive marker for endocrine treatment as well as a prognostic indicator in non-IBC [3, 4]. Commonly, ER and PR expression by IHC analysis is positively associated with response to endocrine treatment and with better prognosis in early-stage ER-positive (ER+) non-IBC [3, 5]. However, the role of these hormone receptors (HRs) in IBC has been inconsistent, according to a retrospective analysis based on a large data registry [6, 7].

We previously investigated the prognostic value of HRs in patients with IBC who underwent neoadjuvant chemotherapy (NAC) and found that HR positivity had no prognostic value for survival after NAC among HR-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+), HR+/HER2-negative (HER2-), and HR-negative (HR-)/HER2+ subtypes [8]. This result was in contrast to those of previous studies showing that the ER+/HER2- subtype demonstrated significantly worse survival outcome compared with ER+/HER2+ or ER-negative (ER-)/HER2+ subtypes [7], or that ER positivity had a significant association with better survival outcome in patients with IBC, regardless of the type of treatment [6]. Although these inconsistencies may be explained by the nature of retrospective analysis, more detailed analysis is needed to understand the mechanism responsible for the differences between HR+ IBC and non-IBC. To elucidate this mechanism, we applied a two-step approach—an IHC analysis and gene expression (GE) analysis focused on the estrogen signaling pathway in IBC.

Our main hypothesis was that HR expression has a prognostic role in HR+/HER2- IBC and that HR+/HER2- IBC has specific GE in the ER signaling pathway that characterizes aggressive biological behavior.

Methods

Patient selection

Our study population consisted of two groups: (1) the IHC study group, which consisted of 866 patients (189 IBC and 677 non-IBC) and (2) the GE study group, which included 389 patients (137 IBC and 252 non-IBC).

IHC study

For the IHC study group, we retrospectively reviewed clinical and pathological information from the breast

cancer electronic medical record management system at The University of Texas MD Anderson Cancer Center between January 1, 1989, and April 30, 2015 ($n = 1731$). A multidisciplinary team, consisting of a medical oncologist, surgical oncologist, radiologist, and nurse, determined the clinical diagnosis of IBC according to the IBC-specific clinical manifestation. This clinical manifestation includes history of rapid onset of breast erythema, edema and/or *peau d'orange*, and/or warm breast, with or without an underlying palpable mass. A history of flattening, crusting, or retraction of the nipple were also considered. We excluded cases with inflammatory skin change secondary to non-IBC.

For patient selection, we first excluded patients who did not have adequate pathological information with which to determine the percentage expression of ER (ER%) and the percentage expression of PR (PR%) ($n = 452$). Next, we excluded patients who had undergone neoadjuvant endocrine therapy ($n = 59$), no definitive surgery ($n = 43$), or insufficient pathological data for pathological complete response (pCR) ($n = 25$) or survival ($n = 11$). We also excluded patients with T stage 0–2 ($n = 275$) because we did not consider these stages to be locally advanced. Finally, we obtained 866 eligible patients, including 189 with IBC and 677 with case-matched stage III non-IBC (Supplementary Fig. 1).

GE study

For the GE study group, we used mRNA expression data from the World IBC Consortium gene database [9]. The World IBC Consortium is a multicenter collaborative project that explores the biology of IBC based on gene expression by applying whole-transcriptome Affymetrix DNA microarrays. This data set includes the comprehensive gene set used in our study of 137 IBC patients and 252 non-IBC patients.

Data collection

Pathological evaluation for IHC study

We obtained the continuous value of percentage HR expression both in ER and PR. We defined ER as positive if ER expression by IHC was 1% or more. HER2 positivity was determined according to the ASCO/CAP guidelines at the time of pathological evaluation. We defined pCR as no invasive components in residual tumor in the primary site or axillary lymph nodes in the surgical specimen [10].

GE evaluation and pathway analysis for GE study

We examined GE differences between patients with HR+/HER2- IBC and HR+/HER2- non-IBC by feature-by-feature linear mixture models and then fitting a beta-uniform mixture model to control for multiple testing [11, 12]. The number of significant genes was counted

for false discovery rates at 1%. We used the Affymetrix U133 annotation package hgu133a.db (Affymetrix, Santa Clara, CA, USA) to export gene symbols for 22,283 probes. We determined upregulation and downregulation by median value of gene expression. After identifying significantly upregulated/downregulated genes in IBC, we looked for enriched canonical pathways that included these genes by using ingenuity pathway analysis (QIAGEN, Germantown, MD, USA). Next, we investigated the relationship between these canonical pathways and the ER signaling pathway.

Statistical analysis

We compared the clinicopathological characteristics between patients with HR+/HER2- IBC and corresponding non-IBC with use of a chi-square test for categorical data and Student *t* test for interval-scaled data. We also used a logistic regression model to determine the association between ER%, PR%, and pCR.

Survival analysis and setting the cutoff points

We performed a survival analysis with two outcomes for the IHC study (distant disease-free survival [DDFS] and overall survival [OS]) and three outcomes for the GE study (recurrence-free survival [RFS], DDFS, and OS). We defined RFS as the time from the date of definitive surgery to the date of locoregional recurrence or distant metastasis, DDFS as the time from the date of definitive surgery to the date of distant metastasis, and OS as the time from the date of definitive surgery to the date of death due to any causes or the date of last follow-up. Survival rates were calculated by using the Kaplan-Meier method, and curves were compared with the log-rank test. In the Cox proportional hazard model, we adjusted for age, menopausal status, histology, cN stage, cT stage, lymphatic invasion, vascular invasion, grade, and mastectomy status. We calculated the hazard ratio for HR expression as 50% increase, which can be thought of as comparing outcomes in two patients, one with ER/PR level X and another with ER/PR level X + 50%. We applied recursive partitioning analysis (RPA) to determine the optimal cutoff points for ER% and PR% that maximized the difference in DDFS. RPA created a regression tree that was divided by certain cutoff points that maximized the difference in outcome and then determined the optimal cutoff points [13].

In addition, we performed an external validation analysis by using an external cohort from the Institut Paoli-Calmettes (Marseille, France). The cohort included 57 patients with HR+/HER2- IBC and 78 patients with stage III HR+/HER2- non-IBC who underwent NAC between February 1, 1993, and February 28, 2015. All statistical analyses were performed two-sided, and $P < 0.05$ was defined as statistically significant. This study

was approved by the Institutional Review Board at MD Anderson Cancer Center (PA17-0491).

Results

IHC analysis

Patient characteristics

Patients with IBC demonstrated significantly higher nuclear grades ($P < 0.001$) and more frequent ductal histology than did those in the non-IBC group ($P = 0.003$). In contrast, positivity for lymphatic and vascular invasion was not significantly different between the non-IBC and the IBC groups. Significantly more patients in the non-IBC group received adjuvant endocrine therapy than did patients in the IBC group ($P = 0.007$, Table 1). There were no significant differences regarding to the radiation therapy between two groups. The Mann-Whitney U test showed that the IBC group had significantly lower ER% and PR% compared with the non-IBC group (median ER%: 85% for IBC vs. 90% for non-IBC, $P = 0.012$; median PR%: 30% for IBC vs. 50% for non-IBC, $P = 0.034$) (Supplementary Fig. 2).

Treatment response, survival analysis, and HR expression

Of 677 study patients with non-IBC, 33 (5%) achieved pCR after NAC; of 189 patients with IBC, 13 (7%) achieved pCR. Our logistic regression model showed that the ER% and PR% were not significantly associated with pCR in either non-IBC or IBC (data not shown). The median follow-up for non-IBC and IBC was 4.0 and 3.8 years, respectively. During follow-up, 90 IBC patients (48%) and 226 non-IBC patients (33%) had distant recurrences; also during this period, 80 IBC patients (42%) and 186 non-IBC patients (27%) died.

In the multivariate analysis, expression of ER% was significantly associated with longer DDFS as well as OS for IBC ($P = 0.0068$ for DDFS and $P < 0.001$ for OS). However, the effect of the PR% was marginal or non-significant, respectively, for DDFS and OS ($P = 0.049$ for DDFS and $P = 0.14$ for OS) (Fig. 1). A similar association between ER expression and survival outcome was observed in non-IBC.

ER% and PR% cutoff points

RPA showed that the optimal cutoff points for DDFS in ER% and PR% in IBC were 91.5 and 9%, respectively (Fig. 2b). The same cutoff points also distinguished OS for IBC (Fig. 2d). In non-IBC, the survival curves for the group with ER% $\geq 91.5\%$ and PR% $\geq 9\%$, and for the group with ER% $< 91.5\%$ and PR% $\geq 9\%$, were overlapped for DDFS and OS (Fig. 2a and c).

We attempted an external validation of the newly established cutoff with use of the external cohort from Institut Paoli-Calmettes. The median follow-up periods for IBC and non-IBC patients were 7.0 and 9.0 years, respectively. During follow-up, 28 IBC patients (49%) and 23 non-IBC patients (30%) had distant recurrences; 20

Table 1 Patient characteristics


Characteristic		non-IBC No. (n = 677)	%	IBC No. (n = 189)	%	P
Age, median (range), y		50 (22–83)		51 (23–75)		0.56
BMI, mean $\pm$ SD, m ²		29.3 $\pm$ 6.8		31.7 $\pm$ 7.5		0.93
Menopausal status						0.002
	Pre	352	(52)	75	(40)	
	Post	304	(45)	108	(57)	
	Unknown	21	(3)	6	(3)	
cT stage						< 0.001
	3	395	(58)	0	(0)	
	4	282	(42)	189	(100)	
	Unknown	0	(0)	0	(0)	
cN stage						0.046
	0	57	(8)	29	(15)	
	1	415	(61)	109	(58)	
	2	69	(10)	18	(10)	
	3	135	(20)	33	(17)	
	Unknown	1	(1)	0	(0)	
Histology						0.003
	Ductal	507	(75)	160	(85)	
	Lobular	103	(15)	12	(6)	
	Mixed	46	(7)	9	(5)	
	Other	21	(3)	8	(4)	
Histological grade						< 0.001
	1	46	(7)	4	(2)	
	2	313	(46)	67	(35)	
	3	288	(43)	107	(57)	
	Unknown	30	(4)	11	(6)	
Lymphatic invasion						0.277
	Positive	389	(57)	116	(61)	
	Negative	271	(40)	67	(36)	
	Unknown	17	(3)	6	(3)	
Vascular invasion						0.512
	Positive	400	(59)	106	(56)	
	Negative	260	(38)	77	(41)	
	Unknown	17	(3)	6	(3)	
NAC regimen						0.308
	A	74	(11)	27	(14)	
	T	28	(4)	5	(2)	
	A + T	572	(84)	156	(83)	
	Other	3	(1)	1	(1)	
Adjuvant chemotherapy						0.001
	Yes	120	(13)	54	(28)	
	No	557	(87)	135	(72)	

Table 1 Patient characteristics (Continued)

Characteristic		non-IBC No. (<i>n</i> = 677)	%	IBC No. (<i>n</i> = 189)	%	<i>P</i>
Adjuvant endocrine therapy	Yes	590	(87)	150	(79)	0.007
	No	87	(13)	39	(21)	
Neoadjuvant radiation therapy	Yes	6	(1)	5	(3)	0.056
	No	671	(99)	184	(97)	
Adjuvant radiation therapy	Yes	612	(90)	163	(86)	0.100
	No	65	(10)	26	(14)	

Abbreviations; IBC inflammatory breast cancer, BMI body mass index, SD standard deviation, NAC neoadjuvant chemotherapy, A anthracycline, T taxane

a. Comparison of hazard ratio for distant disease-free survival according to the change in ER and PR expression



b. Comparison of hazard ratio for overall survival according to the change in ER and PR expression




Fig. 1 Effects of change in ER% and PR% on survival outcomes by multivariate analysis. **a** Comparison of hazard ratio for distant disease-free survival according to the change in ER and PR expression. **b** Comparison of hazard ratio for overall survival according to the change in ER and PR expression




Fig. 2 Survival outcomes according to newly defined cutoff points for ER and PR expression in ER+/HER2- IBC and corresponding non-IBC. **a** Distant disease-free survival by ER and PR levels for non-IBC. **b** Distant disease-free survival by ER and PR levels for IBC **c** Overall survival by ER and PR levels for non-IBC. **d** Overall survival by ER and PR levels for IBC

IBC patients (35%) and 9 non-IBC patients (12%) died. DDFS and OS rates were lower in IBC than in non-IBC patients. Although a similar pattern of survival curves was observed in DDFS and OS for non-IBC group, the survival analysis with optimal grouping for ER% and PR% identified in the training set showed no significant differences in prognosis in the IBC group (Supplementary Fig. 3a-d).

Gene expression analysis

Although the validation study on the outside cohort could not determine the universality of newly detected cutoff points, the IHC study suggested that ER% was associated with significantly better survival outcome in ER+/HER2- IBC than in corresponding non-IBC. This result indicated the difficulty in establishing universal cutoff points for HR+ IBC and the need to deeply investigate the role of the ER signaling pathway at the gene level. To this end, we further compared GE between HR+/HER2- IBC patients and the corresponding non-IBC patients to detect the specific genetic alteration in the ER signaling pathway.

Pathway analysis of significant genes associated with IBC status

The distribution of patient characteristics was not significantly different between the IBC and non-IBC groups (Supplementary Table 1). We identified 97 probe sets that significantly distinguished IBC from non-IBC at a false discovery rate of 1%. Among the 97 probe sets, 13 did not have a gene symbol in the Affymetrix annotation package, and 84 genes remained (Supplementary Table 2).

After the 84 genes associated with IBC were investigated with use of ingenuity pathway analysis, the top 15 canonical pathways in which these genes were included were revealed (Supplementary Fig. 4). However, the number of genes included in each pathway was relatively small (1 to 3). Among the top 15 pathways, the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway, platelet-derived growth factor (PDGF) pathway, insulin receptor signaling pathway, and interleukin-7 (IL-7) signaling pathway overlapped with the ER signaling pathway. Among the upregulated/downregulated genes in those four pathways, *MYC* was the most frequently observed upregulated gene in three of the pathways (Supplementary Table 3).

Survival analysis based on *MYC* expression

The Wilcoxon test showed no significant differences in *MYC* expression levels between patients with HR+/HER2- IBC and those with non-IBC. In IBC patients, a Cox proportional hazard model indicated significant associations between *MYC* level and RFS (hazard ratio, 1.93; 95% confidence interval, 1.09 to 3.43, $P = 0.003$) and between *MYC* level and DDFS (hazard ratio, 2.00; 95% confidence interval, 1.10 to 3.64, $P = 0.028$), but not between *MYC* level and OS (hazard ratio, 1.45; 95% confidence interval, 0.65 to 3.24, $P = 0.38$) in HR+/HER2- IBC (Supplementary Table 4).

Discussion

To the best of our knowledge, the present study was the first to find that the positivity level of ER expression had a significant prognostic role, even in HR+/HER2- IBC. Furthermore, the GE exploratory analyses indicated that *MYC* was the key gene in understanding the biological behavior of HR+/HER2- IBC.

In contrast to the predictive value, we identified the prognostic role of ER in HR+/HER2- IBC. Basically, the HR-positive breast cancer population shows a low percentage of pCR because of tumor dormancy, and as tumor stage becomes more advanced, pCR can be more difficult to obtain [7, 8]. Indeed, the present study showed that only 13 IBC patients (7%) and 33 non-IBC patients (5%) experienced pCR, which was very small compared with the population of patients with early breast cancer. Notably, patients with HR+/HER2- IBC had a wider range of heterogeneity in survival outcome according to ER expression level, and those with high ER expression had a better prognosis, which was similar to that of non-IBC patients. The results indicated that ER expression level also had an important prognostic role even in patients with HR+/HER2- IBC.

The present study also detected the optimal cutoff points for survival in HR+/HER2- IBC at 91.5% for ER and 9% for PR. Furthermore, these cutoff points were IBC-specific since they could not be applied to corresponding non-IBC. Unfortunately, however, the external validation study failed to show the universality of the newly detected cutoff points on prognosis. In fact, the distribution of HR expression was significantly different between MD Anderson's cohort and the validation cohort, showing 72.2 and 80.4% in mean ER and 40.4 and 53.8% in PR for MD Anderson's cohort and the validation cohort, respectively. Accordingly, OS was generally better in the validation cohort than in the MD Anderson cohort (data not shown). The difference in survival was probably due to the fact that most of the patients with IBC at MD Anderson were referred from community clinics and this data set included more complexed or advanced cases with comorbidities. In addition, the

difference in diagnostic criteria for IBC could affect the outcome. Further investigation is needed to establish the globally applicable cutoff point.

In the GE analysis, *MYC* was found to be upregulated in 3 of 4 pathways overlapping the ER pathway, and the gene had a significant impact on survival outcome in IBC. *MYC* is a regulator gene coding for transcriptional factors involved in cell cycle and cell growth. Generally, *MYC* amplification was observed in more aggressive subtypes such as HER2+ and triple-negative types [14], as well as in advanced clinical status [15], leading to poor survival outcome [16, 17]. For IBC, *MYC* has been investigated mainly in the triple-negative type [18, 19]; however, the present study found that *MYC* was also upregulated in HR+/HER2- IBC, leading to a significant association with poor survival outcome.

Generally, *MYC* expression was associated with cell cycle activity with increased cyclin B1 and Ki-67 expression [17] and can be a predictive marker for endocrine therapy resistance [20]. Indeed, we observed *MYC* upregulation in the ERK/MAPK and PDGF pathways, which have a significant role in endocrine therapy resistance [21, 22]. The activation of ERK/mitogen-activated protein kinase induces tamoxifen resistance by altering the level of estrogen-related receptor γ (ERR γ), which is an orphan member of the nuclear receptor superfamily. Furthermore, ERR γ -driven transcriptional activity is impaired by the mutation of ERK target sites, leading to the tamoxifen resistance [21]. For the PDGF pathway, a clinical study of 45 breast cancer patients treated with an aromatase inhibitor showed that the protein expression of PDGF receptor α and β in tumor was significantly increased at the point of relapse and the higher expression was correlated with shorter time to treatment failure [22]. Although the detailed mechanism for endocrine therapy resistance by *MYC* for HR+/HER2- IBC needs to be further investigated, the results in the present study suggest that *MYC* possibly contributed to poor prognosis due to either intrinsic characteristics or endocrine treatment resistance.

Notably, *MYC* upregulation contributed to survival outcome only in RFS and DDFS but not in OS for HR+/HER2- IBC. Previous studies had suggested that IBC has a unique metastatic process characterized by higher lymphatic invasion, tumor embolization, activated inflammatory pathways, and increased growth factors [23]. The *MYC* gene codes transcription factors and regulates every stage of the metastasis process, including cell proliferation, angiogenesis, and epithelial-to-mesenchymal transition [24]. However, it is unclear whether *MYC* has any specific effect on the metastatic process, especially for IBC. We reported that metastasis for IBC was associated with a risk allele at 8q24 where *MYC* located [25]. Moreover, we determined that the *MYC* activation in

IBC was caused by the dysfunctional antagonization of *MYC* by the activation of *SMAD3*, which was located downstream of the TGF- β signaling pathway [26]. Since *MYC* can be activated by upstream signaling pathways and codes many transcriptional factors, more comprehensive gene analysis will be needed to elucidate how *MYC* affects the metastasis process in HR+/HER2- IBC.

The chief limitation of the present study is that we excluded a certain number of patients during the selection process because they did not have a detailed pathological report; most of these patients had been evaluated outside of MD Anderson. Although we cannot estimate the result of excluding these patients, it is possible that HR distribution and the cutoff point may have been different if all cases had been included in the analysis. Moreover, the antibody used for IHC and the definition of HER2 positivity was not consistent over the study period, which possibly affected the overall results.

Conclusions

The present study was the first to find that higher ER expression level was significantly associated with better survival, even in patients with HR+/HER2- IBC. Gene analysis showed that IBC had several activated pathways with *MYC* upregulation compared with corresponding non-IBC. The results indicated that *MYC* may be a key gene for understanding the biological behavior of HR+/HER2- IBC.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12885-020-06940-z>.

Additional file 1: Figure S1. CONSORT diagram. **Figure S2.** Scatter plot of ER% and PR% in IBC and non-IBC. **Figure S3.** Result of external validation for newly defined cutoff points by the cohort from Institut Paoli-Calmettes. **Figure S4.** Top canonical pathways including upregulated/downregulated genes associated with IBC by ingenuity pathway analysis. After analyzing the 84 genes associated with IBC with use of ingenuity pathway analysis, the top 15 canonical pathways, which included those genes, were revealed. The z-score determines whether an upstream transcription regulator has significantly more “activated” predictions than “inhibited” predictions ($z > 0$) or vice versa ($z < 0$). The ratio in the figure means the percentage of included genes in each pathway. All *P* values were unadjusted.

Additional file 2: Table S1. Patient background in gene expression analysis. **Table S2.** Probes and symbols for gene expression analysis. **Table S3.** Upregulated and downregulated genes in four pathways overlapping the estrogen receptor signaling pathway. **Table S4.** The result of the Cox proportional hazard model based on *MYC* expression in ER+/HER2- IBC. Hazard ratio was calculated according to the continuous value of *MYC* expression.

Abbreviations

DDFS: Distant disease-free survival; ER: Estrogen receptor; GE: Gene expression; ERK, extracellular signal-regulated kinase; HER2: Human epidermal growth factor receptor 2; HR: Hormone receptor; HR+: Hormone receptor-positive; HR-: Hormone receptor-negative; IBC: Inflammatory breast cancer; IHC: Immunohistochemical; IL-7: Interleukin-7; MAPK: Mitogen-activated protein kinase; NAC: Neoadjuvant chemotherapy; PDGF: Platelet-derived

growth factor; RFS: Recurrence-free survival; OS: Overall survival; PR: Progesterone receptor; RPA: Recursive partitioning analysis

Acknowledgements

We thank Tamara K. Locke for editing the manuscript, Modest G. Patangan Jr. and Limin Hsu for data collection, and Huiming Sun and Jie S Willey for helping with preparing the protocol.

Authors' contributions

Concept and design: TI, KH, HM, NTU. Data acquisition: TI, KH, HM, LD, SJVL, FB. Data analysis and interpretation: TI, KH, HM, KRH, YW. Manuscript writing: TI. Critical review of the manuscript: TI, KH, MK, KK, KRH, YW, LD, WAW, RML, SJVL, AL, SK, FB, NTU. All authors read and approved the final manuscript.

Funding

The gene analysis part was funded by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program Grant (1R01CA205043-01A1) (NTU), and MD Anderson's Cancer Center Support Grant (P30CA016672).

Availability of data and materials

All analyzed data are included in this published article and its supplementary file. The original data are available upon reasonable request to the corresponding author.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board at MD Anderson Cancer Center (PA17-0491). Informed consent was waived for this retrospective analysis.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ²Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ³Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁴Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁵Department of Oncology, University of Antwerp, Prinsstraat 13, 2000 Antwerpen, Belgium. ⁶Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁷Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁸Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ⁹Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. ¹⁰Laboratory of Predictive Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix-Marseille Université, F-13009 Marseille, France.

Received: 6 February 2020 Accepted: 7 May 2020

Published online: 18 May 2020

References

- Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. *J Natl Cancer Inst.* 2005;97(13):966–75. <https://doi.org/10.1093/jnci/dji172>.
- Gonzalez-Angulo AM, Hennessy BT, Broglio K, Meric-Bernstam F, Cristofanilli M, Giordano SH, Buchholz TA, Sahin A, Singletary SE, Buzdar AU, Hortobagyi GN. Trends for inflammatory breast cancer: is survival improving?

- Oncologist. 2007;12(8):904–12. <https://doi.org/10.1634/theoncologist.12-8-904>.
3. Stendahl M, Ryden L, Nordenskjöld B, Jonsson PE, Landberg G, Jirstrom K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. *Clinical cancer research*: an official journal of the American Association for Cancer Research. 2006; 12(15):4614–8. <https://doi.org/10.1158/1078-0432.ccr-06-0248>.
 4. Liu J, Guo H, Mao K, Zhang K, Deng H, Liu Q. Impact of estrogen receptor-beta expression on breast cancer prognosis: a meta-analysis. *Breast Cancer Res Treat*. 2016;156(1):149–62. <https://doi.org/10.1007/s10549-016-3721-3>.
 5. Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss LK, Malone KE, Burkman RT, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. *BCR*. 2013;15(5):R90. <https://doi.org/10.1186/bcr3486>.
 6. Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W, Wei W, Sun S. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program. *Oncotarget*. 2017. <https://doi.org/10.18632/oncotarget.17217>.
 7. Liu J, Chen K, Jiang W, Mao K, Li S, Kim MJ, Liu Q, Jacobs LK. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. *J Cancer Res Clin Oncol*. 2017;143(1):161–8. <https://doi.org/10.1007/s00432-016-2281-6>.
 8. Masuda H, Brewer TM, Liu DD, Iwamoto T, Shen Y, Hsu L, Willey JS, Gonzalez-Angulo AM, Chavez-MacGregor M, Fouad TM, Woodward WA, Reuben JM, Valero V, Alvarez RH, Hortobagyi GN, Ueno NT. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. *Ann Oncol*. 2014;25(2):384–91. <https://doi.org/10.1093/annonc/mdt525>.
 9. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. *Clin Cancer Res*. 2013;19(17):4685–96. <https://doi.org/10.1158/1078-0432.ccr-12-2549>.
 10. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and bowel project protocol B-27. *J Clin Oncol*. 2003;21(22):4165–74. <https://doi.org/10.1200/jco.2003.12.005>.
 11. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. *Bioinformatics* (Oxford, England). 2003; 19(10):1236–42.
 12. Trabzuni D, Thomson PC. Analysis of gene expression data using a linear mixed model/finite mixture model approach: application to regional differences in the human brain. *Bioinformatics* (Oxford, England). 2014; 30(11):1555–61. <https://doi.org/10.1093/bioinformatics/btu088>.
 13. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. *Psychol Methods*. 2009;14(4):323–48. <https://doi.org/10.1037/a0016973>.
 14. Pereira CB, Leal MF, de Souza CR, Montenegro RC, Rey JA, Carvalho AA, Assumpcao PP, Khayat AS, Pinto GR, Demachki S, de Arruda Cardoso Smith M, Burbano RR. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy. *PLoS One*. 2013;8(3):e60576. <https://doi.org/10.1371/journal.pone.0060576>.
 15. Qu J, Zhao X, Wang J, Liu X, Yan Y, Liu L, Cai H, Qu H, Lu N, Sun Y, Wang F, Wang J, Zhang J. MYC overexpression with its prognostic and clinicopathological significance in breast cancer. *Oncotarget*. 2017;8(55): 93998–4008. <https://doi.org/10.18632/oncotarget.21501>.
 16. Batistatou A, Kotoula V, Bobos M, Kouvatseas G, Zagouri F, Tsolaki E, Gogas H, Kouttras A, Pentheroudakis G, Timotheadou E, Pervana S, Goussia A, Petraki K, Sotiropoulou M, Koletsis T, Razis E, Kosmidis P, Aravantinos G, Papadimitriou C, Pectasides D, Fountzilas G (2018) Correlation of MYC gene and Protein status with breast cancer subtypes and outcome of patients treated with Anthracycline-based adjuvant chemotherapy. Pooled analysis of 2 Hellenic cooperative group phase III trials. *Clinical breast cancer* 18 (1): 53-62.e53. doi:<https://doi.org/10.1016/j.clbc.2017.07.004>.
 17. Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA. MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. *Br J Cancer*. 2016;114(8):917–28. <https://doi.org/10.1038/bjc.2016.46>.
 18. Fernandez SV, Robertson FM, Pei J, Aburto-Chumpitaz L, Mu Z, Chu K, Alpaugh RK, Huang Y, Cao Y, Ye Z, Cai KQ, Boley KM, Klein-Szanto AJ, Devarajan K, Addya S, Cristofanilli M. Inflammatory breast cancer (IBC): clues for targeted therapies. *Breast Cancer Res Treat*. 2013;140(1):23–33. <https://doi.org/10.1007/s10549-013-2600-4>.
 19. Ross JS, Ali SM, Wang K, Khaira D, Palma NA, Chmielecki J, Palmer GA, Morosini D, Elvin JA, Fernandez SV, Miller VA, Stephens PJ, Cristofanilli M. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. *Breast Cancer Res Treat*. 2015;154(1):155–62. <https://doi.org/10.1007/s10549-015-3592-z>.
 20. Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D'Cruz CM (2015) Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. *Oncotarget* 6 (4):2407-2420. Doi:10.18632/oncotarget.2964.
 21. Heckler MM, Thakor H, Schafer CC, Riggins RB. ERK/MAPK regulates ERG expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. *FEBS J*. 2014;281(10):2431–42. <https://doi.org/10.1111/febs.12797>.
 22. Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, Dowsett M, Martin LA. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. *Ann Oncol*. 2013;24(1):126–33. <https://doi.org/10.1093/annonc/mds240>.
 23. Woodward WA. Inflammatory breast cancer: unique biological and therapeutic considerations. *Lancet Oncol*. 2015;16(15):e568–76. [https://doi.org/10.1016/s1470-2045\(15\)00146-1](https://doi.org/10.1016/s1470-2045(15)00146-1).
 24. Dang CV. MYC on the path to cancer. *Cell*. 2012;149(1):22–35. <https://doi.org/10.1016/j.cell.2012.03.003>.
 25. Bertucci F, Lagarde A, Ferrari A, Finetti P, Charafe-Jauffret E, Van Laere S, Adelaide J, Viens P, Thomas G, Birnbaum D, Olschwang S. 8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. *PLoS One*. 2012;7(5):e37943. <https://doi.org/10.1371/journal.pone.0037943>.
 26. Rypens C VBC, Billet C, Hauspy J, Bertucci F, Peter V, Dirix L, Van Laere S. (2018) Inflammatory breast cancer cells are characterized by attenuated SMAD dependent TGFβ signaling leading to impaired cell motility responses. Paper presented at the 2018 San Antonio breast Cancer symposium, San Antonio, TX.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

